Linagliptin vs Teneligliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Linagliptin · Tradjenta
Marketed by Boehringer Ingelheim and partners
NCT00602472 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 1,058 participants, and its primary endpoint was met: adjusted HbA1c change was −0.72% with linagliptin versus −0.10% with placebo (p<0.0001). The evidence is considered moderate because HbA1c is a surrogate measure rather than a hard clinical endpoint.
Reported efficacy
The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years (met)
Result source: NCT01243424
Teneligliptin · Tenelia
Marketed by Tanabe Pharma Corporation and partners
NCT00974090 · Phase 3 · completed
This randomized, double-blind, placebo-controlled Phase 3 trial added teneligliptin 20 mg or placebo to glimepiride in 194 Japanese adults with type 2 diabetes. The primary endpoint was the change in HbA1c at week 12. Teneligliptin lowered HbA1c by 1.0 percentage point more than placebo (p<0.001), so the primary endpoint was met. A 40-week open-label teneligliptin period followed. Source: the peer-reviewed trial report (Kadowaki and Kondo 2014) and CT.gov posted results.
Reported efficacy
HbA1c (Change from Visit 1(Baseline Visit) in HbA1c at Visit 5(week 16)): Change in HbA1c from baseline to week 16, teneligliptin (MP-513) vs placebo (both plus metformin): between-group difference -0.78 percentage points; fasting plasma glucose difference -1.24 mmol/L (22.42 mg/dL). (met)
Result source: NCT01805830
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Linagliptin | Teneligliptin |
|---|---|---|
| HbA1c, change | -0.6% vs 0.1%−0.6 vs placeboNCT00954447129 other results
| -0.7% vs -0.0%−0.7 vs placeboNCT0292406412 other results
|
| Body weight, change (kg) | 1.4 vs -0.0+1.5 vs placeboNCT034295434 other results
| —Not posted · NCT01798238 |
| HbA1c below 7% | 26.9% vs 24.5%+2.4 vs placeboNCT034295437 other results
| —Not posted · NCT01798238 |
| Fasting plasma glucose, change | -0.4 vs 0.3−0.6 vs placeboNCT0095444795 other results
| -0.8 vs 0.2−0.9 vs placeboNCT0292406413 other results
|
| 3-point MACE (% with event) | 20.7% vs 21.2%vs GlimepirideNCT012434242 other results
| —Not posted · NCT01798238 |
HbA1c, change
- Linagliptin
- -0.6% vs 0.1%−0.6 vs placeboNCT00954447
129 other results
- -0.7% vs -0.1% NCT00602472
- -0.5% vs 0.1% NCT00601250
- -0.6% vs -0.0% NCT01792518
- -0.7% vs -0.2% NCT01214239
- -0.7% vs -0.1% NCT01215097
- -0.8% vs -0.3% NCT00996658
- -0.8% vs -0.3% NCT01194830
- -0.6% vs 0.0% NCT01084005
- -0.5% vs -0.1% NCT01087502
- -1.1% vs -0.6% NCT00641043
- -0.4% vs 0.3% NCT00621140
- -0.9% vs -0.3% NCT02489968
- -0.6% vs 0.1% NCT01734785
- -0.9% vs -0.3% NCT02489968
- -0.7% vs 0.1% NCT01734785
- -0.6% vs -0.2% NCT02897349
- -1.3% vs -1.6% NCT01708902
- -1.3% vs -1.7% NCT01708902
- 0.3% vs -0.2% NCT03429543
- -0.4% vs -0.7% NCT01183013
- -0.8% vs -0.7% NCT01183013
- -1.1% vs -0.7% NCT01183013
- -1.3% vs -0.7% NCT01183013
- -2.1% vs -1.6% NCT01708902
- -2.3% vs -1.6% NCT01708902
- -2.2% vs -1.7% NCT01708902
- -2.4% vs -1.7% NCT01708902
- -0.6% vs 0.0% NCT00954447
- -0.6% vs 0.0% NCT00954447
- -0.6% vs 0.0% NCT00954447
- -0.5% vs 0.1% NCT00954447
- -0.5% vs 0% NCT00954447
- -0.5% vs 0.1% NCT00954447
- -0.8% vs -0.1% NCT00602472
- -0.7% vs -0.2% NCT01214239
- -0.7% vs -0.2% NCT01215097
- -0.7% vs -0.2% NCT01214239
- -0.6% vs -0.1% NCT01215097
- -0.9% vs -0.4% NCT00996658
- -0.8% vs -0.3% NCT01194830
- -0.6% vs 0.0% NCT01084005
- -0.6% vs -0.1% NCT01214239
- -0.7% vs -0.1% NCT01215097
- -0.8% vs -0.3% NCT00996658
- -0.7% vs -0.2% NCT01194830
- -0.6% vs -0.0% NCT01084005
- -0.5% vs -0.1% NCT01214239
- -0.5% vs -0.0% NCT01215097
- -0.6% vs -0.2% NCT00996658
- -0.5% vs 0.1% NCT00601250
- -0.4% vs -0.1% NCT01084005
- -1.1% vs -0.6% NCT00641043
- -0.5% vs 0.2% NCT00621140
- -0.8% vs -0.1% NCT00602472
- -0.5% vs 0.1% NCT00601250
- -0.8% vs -0.3% NCT00641043
- -0.5% vs 0.2% NCT00621140
- -0.7% vs -0.2% NCT00602472
- -0.4% vs 0.1% NCT00601250
- -0.4% vs -0.0% NCT00641043
- -0.4% vs 0.1% NCT00621140
- -0.6% vs -0.2% NCT01194830
- -0.5% vs 0.1% NCT03429543
- 0.1% vs 0.1% NCT01243424
- -0.4% vs -0.7% NCT01183013
- -0.5% vs -0.5% NCT01087502
- -0.5% vs -0.5% NCT01087502
- -0.5% vs -0.5% NCT01087502
- -0.4% vs -0.6% NCT01183013
- -0.4% vs -0.7% NCT01183013
- -0.5% vs -0.3% NCT01087502
- -0.5% vs -0.4% NCT01087502
- -0.4% vs -0.4% NCT01183013
- -0.5% vs -0.1% NCT01087502
- -0.5% vs -0.1% NCT01087502
- -0.4% vs -0.2% NCT01087502
- -0.2% vs -0.2% NCT01183013
- -0.3% vs -0.1% NCT01087502
- -0.4% vs -0.2% NCT01087502
- -0.4% vs -0.3% NCT01087502
- -0.8% vs -0.7% NCT01183013
- -1.1% vs -0.7% NCT01183013
- -1.2% vs -0.7% NCT01183013
- -0.8% vs -0.6% NCT01183013
- -1.1% vs -0.6% NCT01183013
- -1.2% vs -0.6% NCT01183013
- -0.9% vs -0.7% NCT01183013
- -1.1% vs -0.7% NCT01183013
- -1.3% vs -0.7% NCT01183013
- -0.7% vs -0.4% NCT01183013
- -0.9% vs -0.4% NCT01183013
- -1.0% vs -0.4% NCT01183013
- -0.4% vs -0.2% NCT01183013
- -0.5% vs -0.2% NCT01183013
- -0.6% vs -0.2% NCT01183013
- -0.3% vs -0.1% NCT00915772
- -0.3% vs -0.1% NCT00915772
- -0.4% vs -0.1% NCT00915772
- -0.4% vs -0.1% NCT00915772
- -1.3% vs -1.2% NCT00915772
- -1.7% vs -1.2% NCT00915772
- -0.2% vs -0.1% NCT00915772
- -0.3% vs -0.1% NCT00915772
- -0.3% vs -0.1% NCT00915772
- -0.3% vs -0.1% NCT00915772
- -1.3% vs -1.2% NCT00915772
- -1.6% vs -1.2% NCT00915772
- -0.3% vs -0.1% NCT00915772
- -0.2% vs -0.1% NCT00915772
- -1.4% vs -1.2% NCT00915772
- -1.7% vs -1.2% NCT00915772
- -1.4% vs -1.3% NCT00915772
- -1.6% vs -1.3% NCT00915772
- -1.3% vs -1.3% NCT00915772
- -1.6% vs -1.3% NCT00915772
- -1.0% vs -0.4% NCT02240680
- -0.5% vs 0.3% NCT01012037
- -0.5% vs 0.3% NCT01012037
- -1.0% vs -1.0% NCT01438814
- -0.6% vs 0.3% NCT01012037
- -0.3% vs 0.3% NCT01012037
- -0.5% vs 0.3% NCT01012037
- -0.3% vs 0.3% NCT01012037
- -0.8% vs -0.8% NCT01438814
- -0.3% vs -0.3% NCT01438814
- 7.6% vs 8% NCT02004366
- 6.6% vs 8% NCT02004366
- 7% vs 8% NCT02004366
- 8.6% vs 8% NCT02004366
- Teneligliptin
- -0.7% vs -0.0%−0.7 vs placeboNCT02924064
12 other results
- -0.9% vs -0.1% NCT02916706
- -0.6% vs 0.2% NCT00998881
- -0.9% vs 0% NCT02354222
- -0.7% vs 0.3% NCT00974090
- -0.8% vs 0.1% NCT00628212
- -0.8% vs 0.1% NCT00628212
- -0.9% vs -0.3% NCT00971243
- -0.9% vs 0.1% NCT00628212
- -0.8% vs -0.3% NCT00971243
- -0.7% vs -0.3% NCT00971243
- -0.6% vs -0.3% NCT00971243
- -0.9% vs -0.1% NCT02081599
Body weight, change (kg)
- Linagliptin
- 1.4 vs -0.0+1.5 vs placeboNCT03429543
4 other results
- -2.5 vs -0.3 NCT01734785
- -3.1 vs -0.3 NCT01734785
- 2.7 vs -0.0 NCT03429543
- -0.4 vs -1.1 NCT01438814
- Teneligliptin
- —Not posted · NCT01798238
HbA1c below 7%
- Linagliptin
- 26.9% vs 24.5%+2.4 vs placeboNCT03429543
7 other results
- 13.9% vs 8.2% NCT02897349
- 16.7% vs 24.5% NCT03429543
- 43.6% vs 50% NCT01708902
- 72.1% vs 50% NCT01708902
- 77.1% vs 50% NCT01708902
- 33% vs 10% NCT01012037
- 34% vs 10% NCT01012037
- Teneligliptin
- —Not posted · NCT01798238
Fasting plasma glucose, change
- Linagliptin
- -0.4 vs 0.3−0.6 vs placeboNCT00954447
95 other results
- -0.3 vs 0.2 NCT00954447
- -0.1 vs 0.0 NCT00954447
- -0.3 vs 0.5 NCT00602472
- -0.5 vs 0.1 NCT01214239
- -0.6 vs -0.1 NCT01215097
- -0.4 vs 0 NCT00954447
- -0.2 vs 0.1 NCT00954447
- -0.6 vs 0.0 NCT00996658
- -0.6 vs 0.6 NCT00601250
- -0.3 vs 0.4 NCT00602472
- -0.6 vs 0.6 NCT00601250
- -0.5 vs 0.3 NCT00602472
- -0.7 vs 0.2 NCT00601250
- -0.6 vs 0.3 NCT00602472
- -0.7 vs 0.3 NCT00601250
- -1.3 vs -0.6 NCT01194830
- -0.6 vs -0.1 NCT01214239
- -0.7 vs -0.1 NCT01215097
- -0.3 vs -0.1 NCT00954447
- -0.4 vs -0.2 NCT00954447
- -0.6 vs 0.6 NCT01084005
- -0.5 vs -0.1 NCT00996658
- -0.7 vs 0.5 NCT01084005
- -0.6 vs -0.1 NCT01214239
- -0.8 vs -0.3 NCT01215097
- -0.4 vs -0.0 NCT00954447
- -0.4 vs 0.2 NCT00996658
- -0.8 vs 0.4 NCT01084005
- -0.7 vs -0.0 NCT01214239
- -0.9 vs 0.3 NCT01215097
- -0.2 vs 0.7 NCT00996658
- -0.8 vs 0.3 NCT01084005
- -1.8 vs 0.3 NCT01734785
- -1.5 vs 0.3 NCT01734785
- -1.8 vs -1.0 NCT00641043
- -0.5 vs 0.8 NCT00621140
- -1.8 vs -1.1 NCT00641043
- -0.4 vs 0.7 NCT00621140
- -1.9 vs -1.1 NCT00641043
- -0.6 vs 0.6 NCT00621140
- -1.9 vs -0.9 NCT00641043
- -0.6 vs 0.4 NCT00621140
- -0.8 vs -1.7 NCT01708902
- -0.3 vs -1.2 NCT01183013
- -0.7 vs -0.5 NCT01087502
- -0.3 vs -0.5 NCT01087502
- -0.5 vs -0.5 NCT01087502
- -0.1 vs -1.6 NCT01183013
- -0.4 vs -1.1 NCT01183013
- 0 vs -1.4 NCT01183013
- -0.1 vs -0.6 NCT01087502
- -0.4 vs -1.2 NCT01183013
- 0.0 vs 0.5 NCT01087502
- -0.3 vs 0.3 NCT01087502
- -0.6 vs 0.5 NCT01087502
- -0.1 vs -0.0 NCT01087502
- -0.2 vs -0.9 NCT01183013
- -0.6 vs 0.5 NCT01087502
- -0.1 vs -0.1 NCT01087502
- 0.2 vs -0.2 NCT01087502
- -0.9 vs -1.2 NCT01183013
- -1.8 vs -1.2 NCT01183013
- -1.8 vs -1.2 NCT01183013
- -1.1 vs -1.6 NCT01183013
- -1.5 vs -1.6 NCT01183013
- -1.9 vs -1.6 NCT01183013
- -1.1 vs -1.1 NCT01183013
- -1.7 vs -1.1 NCT01183013
- -1.7 vs -1.1 NCT01183013
- -1 vs -1.4 NCT01183013
- -1.5 vs -1.4 NCT01183013
- -1.9 vs -1.4 NCT01183013
- -1 vs -1.2 NCT01183013
- -1.7 vs -1.2 NCT01183013
- -1.6 vs -1.2 NCT01183013
- -1.1 vs -0.9 NCT01183013
- -1.5 vs -0.9 NCT01183013
- -1.6 vs -0.9 NCT01183013
- -2.2 vs -1.7 NCT01708902
- -2.6 vs -1.7 NCT01708902
- -0.7 vs -0.1 NCT00915772
- -0.7 vs -0.1 NCT00915772
- -0.8 vs -0.4 NCT00915772
- -0.8 vs -0.4 NCT00915772
- -0.7 vs -0.2 NCT00915772
- -0.8 vs -0.2 NCT00915772
- -0.5 vs -0.4 NCT00915772
- -0.7 vs -0.4 NCT00915772
- -0.7 vs -0.2 NCT00915772
- -0.6 vs -0.2 NCT00915772
- -0.4 vs -0.3 NCT00915772
- -0.6 vs -0.3 NCT00915772
- -1.2 vs -0.2 NCT01012037
- -0.9 vs -0.2 NCT01012037
- -1.4 vs -1.5 NCT01438814
- Teneligliptin
- -0.8 vs 0.2−0.9 vs placeboNCT02924064
13 other results
- -1.2 vs -0.1 NCT02916706
- -1.1 vs -0.0 NCT00998881
- -1.1 vs -0.4 NCT01072331
- -1.1 vs -0.4 NCT01072331
- -0.3 vs 0.6 NCT02354222
- -0.8 vs 0.2 NCT00628212
- -0.8 vs 0.2 NCT00628212
- -1.2 vs -0.2 NCT00971243
- -0.9 vs 0.2 NCT00628212
- -1.0 vs -0.2 NCT00971243
- -0.8 vs -0.2 NCT00971243
- -0.9 vs -0.2 NCT00971243
- -0.3 vs 0.4 NCT02081599
3-point MACE (% with event)
- Linagliptin
- 20.7% vs 21.2%vs GlimepirideNCT01243424
2 other results
- 11.8% vs 12% NCT01243424
- 12.4% vs 12.1% NCT01897532
- Teneligliptin
- —Not posted · NCT01798238
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety
Coverage. Linagliptin: 7 of 7 rows · Teneligliptin: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Linagliptin Rows use multiple source trials | Teneligliptin Rows use multiple source trials |
|---|---|---|
| Fasting Plasma Glucose absolute change · mmol/L No placebo or comparator arm | -1.68 mmol/L @ 24wk*5 mga,b,c,d NCT01512979 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -30.2 mg/dL as posted show 3 more doses-1.67 mmol/L @ 24wk*5 mg NCT01512979 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -30.1 mg/dL as posted -2.61 mmol/L @ 24wk*5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -47.1 mg/dL as posted -2.61 mmol/L @ 24wk*5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -47.1 mg/dL as posted | -0.69 mmol/L @ 52wk*a,b,c,d NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -12.4 mg/dL as posted show 1 more dose-0.94 mmol/L @ 52wk* NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -17 mg/dL as posted |
| HbA1c absolute change · percentage points No placebo or comparator arm | -2.02% (n=113) @ 24wk5 mga,b,c NCT01512979 · Phase 4 · registry result, not featured evidence show 3 more doses-2.01% (n=113) @ 24wk5 mg NCT01512979 · Phase 4 · registry result, not featured evidence -2.81% (n=132) @ 24wk5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination -2.81% (n=132) @ 24wk5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination | -0.94% @ 24wkteneligliptin 20mgb,c NCT01798238 · Phase 3 · sponsor-reported, not registry data |
| PPG 2h Change mg/dL absolute change · mmol/L | -2.71 vs 1.01 placebo mmol/L @ 24wk*c,e NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -48.86 mg/dL as posted 3 other source trials-1.78 vs 0 placebo mmol/L @ 24wk* NCT02897349 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -32.01 mg/dL as posted -2.15 vs -2.04 placebo mmol/L @ 24wk*5 mg NCT01194830 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -38.74 mg/dL as posted -1.86 vs 1.38 placebo mmol/L @ 24wk* NCT00621140 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -33.51 mg/dL as posted | -1.96 vs 0.13 placebo mmol/L @ 24wk*c,e NCT02354222 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -35.3 mg/dL as posted |
| Dropout rate | 7.3%f NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 57 more results7.5% NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —5 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 4.3% NCT01243424 · Phase 3 0% NCT02467478 · Phase 4 · registry result, not featured evidence 15%5 mg per day NCT02372630 · Phase 4 · registry result, not featured evidence 24% NCT01897532 · Phase 4 · registry result, not featured evidence 5.3%5 mg NCT02240680 · Phase 4 · registry result, not featured evidence —5 mg NCT02240680 · Phase 4 · registry result, not featured evidence —5 mg NCT02240680 · Phase 4 · registry result, not featured evidence 0%Linagliptin In-hospital NCT02004366 · Phase 4 · registry result, not featured evidence —Linagliptin on Discharge NCT02004366 · Phase 4 · registry result, not featured evidence —Linagliptin+50%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination —Linagliptin+80%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination 20% NCT02350478 · Phase 4 · registry result, not featured evidence 0% NCT01969084 · Phase 4 · registry result, not featured evidence 14%5 mg NCT01512979 · Phase 4 · registry result, not featured evidence 11.9%5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination 4.1%5 mg once daily + metformin once daily NCT01438814 · Phase 4 · registry result, not featured evidence · combination 5.8% NCT02897349 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 3.8%5 mg NCT01792518 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination —5 mg NCT01708902 · Phase 3 · registry result, not featured evidence 9.9%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence —5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence 11.6%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence —5 mg QD, then 2.5 mg / Metformin after week 12 NCT01708902 · Phase 3 · registry result, not featured evidence · combination —2.5 mg / 1000 mg NCT01708902 · Phase 3 · registry result, not featured evidence · combination 9.7%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination —2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 10.9%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 6.8%2.5 mg / 500 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 22.2%5 mg NCT01183013 · Phase 3 · registry result, not featured evidence 28.6%5 mg + 15 mg / 5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 33.8%5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 27.8%5 mg + 45 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 6.8%5 mg NCT01087502 · Phase 3 · registry result, not featured evidence 9%5 mg NCT01214239 · Phase 3 · registry result, not featured evidence 6.8%5 mg once daily NCT01215097 · Phase 3 · registry result, not featured evidence 11.3%5 mg tablet NCT00996658 · Phase 3 · registry result, not featured evidence 2.4%A-GI+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 3.7%Bigu+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 12.1%Glin+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 6.8%Glit+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 7.7%SU+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 24.5%5 mg NCT01194830 · Phase 3 · registry result, not featured evidence 13.9%5 mg NCT00954447 · Phase 3 · registry result, not featured evidence 17%linagliptin 2.5 mg bid + metformin 1000 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 20.4%linagliptin 2.5 mg bid + metformin 500 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 9.9%5 mg NCT01084005 · Phase 3 · registry result, not featured evidence 21.2% NCT00740051 · Phase 3 · registry result, not featured evidence 5.8% NCT00641043 · Phase 3 · registry result, not featured evidence · combination 5.4% NCT00621140 · Phase 3 · registry result, not featured evidence 4.5%5 mg once daily NCT01012037 · Phase 2 · registry result, not featured evidence 7.2%2.5 mg twice daily NCT01012037 · Phase 2 · registry result, not featured evidence | 1%Teneli / Teneli + SUg NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 28 more results—Teneli/Teneli + SU (Data Through W NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 —Teneli/Teneli + SU (Data Through W NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 10.6%Teneligliptin NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 15.7%Teneligliptin + Sulfonylurea NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.6%Teneli (Teneligliptin) /Teneli + I NCT02081599 · Phase 4 · registry result, not featured evidence · combination —Teneli (Teneligliptin) /Teneli + I NCT02081599 · Phase 4 · registry result, not featured evidence · combination —Teneli (Teneligliptin)/Teneli + In NCT02081599 · Phase 4 · registry result, not featured evidence · combination 19.5%20 mg NCT02924064 · Phase 3 · registry result, not featured evidence · combination 11.8%20 mg NCT02916706 · Phase 3 · registry result, not featured evidence 7.2% NCT02220907 · Phase 3 · registry result, not featured evidence · combination 5.2% NCT02354222 · Phase 3 · registry result, not featured evidence · combination 7.1%Teneligliptin NCT01301833 · Phase 3 · registry result, not featured evidence 9.3%Teneligliptin and Alpha-glucosidas NCT01301833 · Phase 3 · registry result, not featured evidence · combination 7.4%Teneligliptin and Biguanide NCT01301833 · Phase 3 · registry result, not featured evidence · combination 10%Teneligliptin and Glinide NCT01301833 · Phase 3 · registry result, not featured evidence · combination 0%20 mg NCT01072331 · Phase 3 · registry result, not featured evidence 0%10 mg NCT01072331 · Phase 3 · registry result, not featured evidence 2%20 mg NCT00998881 · Phase 3 · registry result, not featured evidence —40 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 15.9%40 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination —20 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 20.9%20 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination —10 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 11.8%10 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 21.8%5 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 3.8%20 mg NCT00628212 · Phase 2 · registry result, not featured evidence 1.2%10 mg NCT00628212 · Phase 2 · registry result, not featured evidence 6.2%40 mg NCT00628212 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 2.9%f NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 57 more results1.7% NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —5 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 — NCT01243424 · Phase 3 — NCT02467478 · Phase 4 · registry result, not featured evidence —5 mg per day NCT02372630 · Phase 4 · registry result, not featured evidence 10.3% NCT01897532 · Phase 4 · registry result, not featured evidence 4%5 mg NCT02240680 · Phase 4 · registry result, not featured evidence —5 mg NCT02240680 · Phase 4 · registry result, not featured evidence —5 mg NCT02240680 · Phase 4 · registry result, not featured evidence —Linagliptin In-hospital NCT02004366 · Phase 4 · registry result, not featured evidence —Linagliptin on Discharge NCT02004366 · Phase 4 · registry result, not featured evidence —Linagliptin+50%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination —Linagliptin+80%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination — NCT02350478 · Phase 4 · registry result, not featured evidence 0% NCT01969084 · Phase 4 · registry result, not featured evidence 1.3%5 mg NCT01512979 · Phase 4 · registry result, not featured evidence 1.3%5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination 0.9%5 mg once daily + metformin once daily NCT01438814 · Phase 4 · registry result, not featured evidence · combination 2.9% NCT02897349 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 2.2%5 mg NCT01792518 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination —5 mg NCT01708902 · Phase 3 · registry result, not featured evidence 4.2%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence —5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence 2%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence —5 mg QD, then 2.5 mg / Metformin after week 12 NCT01708902 · Phase 3 · registry result, not featured evidence · combination —2.5 mg / 1000 mg NCT01708902 · Phase 3 · registry result, not featured evidence · combination 6.9%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination —2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 4.8%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 1.4%2.5 mg / 500 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 3.7%5 mg NCT01183013 · Phase 3 · registry result, not featured evidence 7.9%5 mg + 15 mg / 5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 7.5%5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 4.5%5 mg + 45 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 3.4%5 mg NCT01087502 · Phase 3 · registry result, not featured evidence 2%5 mg NCT01214239 · Phase 3 · registry result, not featured evidence 1.5%5 mg once daily NCT01215097 · Phase 3 · registry result, not featured evidence 2.7%5 mg tablet NCT00996658 · Phase 3 · registry result, not featured evidence 1.2%A-GI+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 2.4%Bigu+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 9.1%Glin+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 0%Glit+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 4.9%SU+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 1.8%5 mg NCT01194830 · Phase 3 · registry result, not featured evidence 4%5 mg NCT00954447 · Phase 3 · registry result, not featured evidence 6.4%linagliptin 2.5 mg bid + metformin 1000 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 5.8%linagliptin 2.5 mg bid + metformin 500 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 4.9%5 mg NCT01084005 · Phase 3 · registry result, not featured evidence 2.6% NCT00740051 · Phase 3 · registry result, not featured evidence 1.5% NCT00641043 · Phase 3 · registry result, not featured evidence · combination 1.5% NCT00621140 · Phase 3 · registry result, not featured evidence 1.3%5 mg once daily NCT01012037 · Phase 2 · registry result, not featured evidence 3.6%2.5 mg twice daily NCT01012037 · Phase 2 · registry result, not featured evidence | 1%Teneli / Teneli + SUg NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 28 more results—Teneli/Teneli + SU (Data Through W NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 —Teneli/Teneli + SU (Data Through W NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.6%Teneligliptin NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 9%Teneligliptin + Sulfonylurea NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3 0%Teneli (Teneligliptin) /Teneli + I NCT02081599 · Phase 4 · registry result, not featured evidence · combination —Teneli (Teneligliptin) /Teneli + I NCT02081599 · Phase 4 · registry result, not featured evidence · combination —Teneli (Teneligliptin)/Teneli + In NCT02081599 · Phase 4 · registry result, not featured evidence · combination 1.6%20 mg NCT02924064 · Phase 3 · registry result, not featured evidence · combination 0%20 mg NCT02916706 · Phase 3 · registry result, not featured evidence 4.6% NCT02220907 · Phase 3 · registry result, not featured evidence · combination 0% NCT02354222 · Phase 3 · registry result, not featured evidence · combination 3.3%Teneligliptin NCT01301833 · Phase 3 · registry result, not featured evidence 6.7%Teneligliptin and Alpha-glucosidas NCT01301833 · Phase 3 · registry result, not featured evidence · combination 5.3%Teneligliptin and Biguanide NCT01301833 · Phase 3 · registry result, not featured evidence · combination 6.3%Teneligliptin and Glinide NCT01301833 · Phase 3 · registry result, not featured evidence · combination —20 mg NCT01072331 · Phase 3 · registry result, not featured evidence —10 mg NCT01072331 · Phase 3 · registry result, not featured evidence 2%20 mg NCT00998881 · Phase 3 · registry result, not featured evidence —40 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 2.3%40 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination —20 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 2.2%20 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination —10 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 3.2%10 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 2.3%5 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 1.3%20 mg NCT00628212 · Phase 2 · registry result, not featured evidence 0%10 mg NCT00628212 · Phase 2 · registry result, not featured evidence 2.5%40 mg NCT00628212 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 3.2%f NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 57 more results3.4% NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 10.4%5 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 46.4% NCT01243424 · Phase 3 7.1% NCT02467478 · Phase 4 · registry result, not featured evidence 0%5 mg per day NCT02372630 · Phase 4 · registry result, not featured evidence 37% NCT01897532 · Phase 4 · registry result, not featured evidence —5 mg NCT02240680 · Phase 4 · registry result, not featured evidence 12.6%5 mg NCT02240680 · Phase 4 · registry result, not featured evidence 25%5 mg NCT02240680 · Phase 4 · registry result, not featured evidence 0.8%Linagliptin In-hospital NCT02004366 · Phase 4 · registry result, not featured evidence 13%Linagliptin on Discharge NCT02004366 · Phase 4 · registry result, not featured evidence 15.1%Linagliptin+50%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination 23.1%Linagliptin+80%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination 15% NCT02350478 · Phase 4 · registry result, not featured evidence 5.3% NCT01969084 · Phase 4 · registry result, not featured evidence 1.3%5 mg NCT01512979 · Phase 4 · registry result, not featured evidence 1.9%5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination 0.6%5 mg once daily + metformin once daily NCT01438814 · Phase 4 · registry result, not featured evidence · combination 9.6% NCT02897349 · Phase 3 · registry result, not featured evidence 5.2%25 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 0.9%10 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 9.3%5 mg NCT01792518 · Phase 3 · registry result, not featured evidence 3.6%25 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination 4.5%10 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination 0%5 mg NCT01708902 · Phase 3 · registry result, not featured evidence —5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence 1.4%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence 1.4%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence 3.2%5 mg QD, then 2.5 mg / Metformin after week 12 NCT01708902 · Phase 3 · registry result, not featured evidence · combination 1.5%2.5 mg / 1000 mg NCT01708902 · Phase 3 · registry result, not featured evidence · combination —2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 1.4%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 2.7%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 0.7%2.5 mg / 500 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 6.7%5 mg NCT01183013 · Phase 3 · registry result, not featured evidence 7.1%5 mg + 15 mg / 5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 11.3%5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 7.5%5 mg + 45 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 24.8%5 mg NCT01087502 · Phase 3 · registry result, not featured evidence 0.5%5 mg NCT01214239 · Phase 3 · registry result, not featured evidence 2%5 mg once daily NCT01215097 · Phase 3 · registry result, not featured evidence 2.2%5 mg tablet NCT00996658 · Phase 3 · registry result, not featured evidence 8.2%A-GI+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 9.8%Bigu+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 7.6%Glin+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 2.7%Glit+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 4.9%SU+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 0.9%5 mg NCT01194830 · Phase 3 · registry result, not featured evidence 13.8%5 mg NCT00954447 · Phase 3 · registry result, not featured evidence 8.2%linagliptin 2.5 mg bid + metformin 1000 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 5.3%linagliptin 2.5 mg bid + metformin 500 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 8.6%5 mg NCT01084005 · Phase 3 · registry result, not featured evidence 0.7% NCT00740051 · Phase 3 · registry result, not featured evidence 3.1% NCT00641043 · Phase 3 · registry result, not featured evidence · combination 3% NCT00621140 · Phase 3 · registry result, not featured evidence 2.2%5 mg once daily NCT01012037 · Phase 2 · registry result, not featured evidence 4%2.5 mg twice daily NCT01012037 · Phase 2 · registry result, not featured evidence | —Teneli / Teneli + SUg NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 28 more results0%Teneli/Teneli + SU (Data Through W NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 7.3%Teneli/Teneli + SU (Data Through W NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 4%Teneligliptin NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 7.9%Teneligliptin + Sulfonylurea NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3 —Teneli (Teneligliptin) /Teneli + I NCT02081599 · Phase 4 · registry result, not featured evidence · combination 6.5%Teneli (Teneligliptin) /Teneli + I NCT02081599 · Phase 4 · registry result, not featured evidence · combination 1.3%Teneli (Teneligliptin)/Teneli + In NCT02081599 · Phase 4 · registry result, not featured evidence · combination 3.2%20 mg NCT02924064 · Phase 3 · registry result, not featured evidence · combination 4.7%20 mg NCT02916706 · Phase 3 · registry result, not featured evidence 7.2% NCT02220907 · Phase 3 · registry result, not featured evidence · combination 1.3% NCT02354222 · Phase 3 · registry result, not featured evidence · combination 6.6%Teneligliptin NCT01301833 · Phase 3 · registry result, not featured evidence 8%Teneligliptin and Alpha-glucosidas NCT01301833 · Phase 3 · registry result, not featured evidence · combination 6.3%Teneligliptin and Biguanide NCT01301833 · Phase 3 · registry result, not featured evidence · combination 3.8%Teneligliptin and Glinide NCT01301833 · Phase 3 · registry result, not featured evidence · combination 0%20 mg NCT01072331 · Phase 3 · registry result, not featured evidence 0%10 mg NCT01072331 · Phase 3 · registry result, not featured evidence 0%20 mg NCT00998881 · Phase 3 · registry result, not featured evidence 5.7%40 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination —40 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 3.3%20 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination —20 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 4.3%10 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination —10 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 4.6%5 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 0%20 mg NCT00628212 · Phase 2 · registry result, not featured evidence 0%10 mg NCT00628212 · Phase 2 · registry result, not featured evidence 0%40 mg NCT00628212 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | f hypoglycaemia 22.7% (placebo 14.8%) upper respiratory tract infection 5.8% (placebo 9.1%) hyperglycaemia 5.6% (placebo 8.7%) NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 50 more resultshyperglycaemia 5.2% (placebo 14.7%) nasopharyngitis 5.2% (placebo 5.1%) NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 5 mg hypoglycaemia 20.8% (placebo 12.1%) headache 15.6% (placebo 15.5%) blood ketone body increased 10.4% (placebo 3.4%) NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 hypoglycaemia 29.3% (placebo 28.8%) hypertension 6.2% (placebo 6.7%) hyperglycaemia 6% (placebo 6.9%) NCT01897532 · Phase 4 · registry result, not featured evidence 5 mg hypoglycaemia 33.8% (placebo 25.2%) viral upper respiratory tract infection 7.3% (placebo 5.3%) urinary tract infection 6.6% (placebo 6%) NCT02240680 · Phase 4 · registry result, not featured evidence 5 mg hypoglycaemia 38.5% (placebo 25.2%) viral upper respiratory tract infection 21.2% (placebo 5.3%) bronchitis 9.6% (placebo 2.6%) NCT02240680 · Phase 4 · registry result, not featured evidence infections 5.5% renal 4.7% surgical reintervention 4.7% NCT02004366 · Phase 4 · registry result, not featured evidence gastrointestinal 1.1% musculoskeletal 1.1% skin 1.1% NCT02004366 · Phase 4 · registry result, not featured evidence gastrointestinal 1.1% hematologic 0% infections 0% NCT02004366 · Phase 4 · registry result, not featured evidence · combination gastrointestinal 0% hematologic 0% infections 0% NCT02004366 · Phase 4 · registry result, not featured evidence · combination dorsal pain 5% (placebo 0%) nausea 5% (placebo 4.3%) toothache 5% (placebo 0%) NCT02350478 · Phase 4 · registry result, not featured evidence increased creatinine and bun, reduced gfr 5.3% (placebo 13.6%) pneumonia 5.3% (placebo 0%) cramping in the calf muscle during the graded exercise test 0% (placebo 4.5%) NCT01969084 · Phase 4 · registry result, not featured evidence 5 mg dyslipidaemia 14% hyperglycaemia 12.7% urinary tract infection 8.9% NCT01512979 · Phase 4 · registry result, not featured evidence 5 mg + Metformin dyslipidaemia 8.8% headache 6.3% urinary tract infection 6.3% NCT01512979 · Phase 4 · registry result, not featured evidence · combination 5 mg once daily + metformin once daily diarrhoea 18% abdominal pain 6.7% nausea 6.7% NCT01438814 · Phase 4 · registry result, not featured evidence · combination hypoglycaemia 17.3% (placebo 12.7%) upper respiratory tract infection 13.5% (placebo 12.7%) hyperuricaemia 5.8% (placebo 1%) NCT02897349 · Phase 3 · registry result, not featured evidence 25 mg + 5 mg viral upper respiratory tract infection 26.7% (placebo 22.2%) blood ketone body increased 13.8% (placebo 10.2%) back pain 6% (placebo 2.8%) NCT02489968 · Phase 3 · registry result, not featured evidence · combination 10 mg + 5 mg viral upper respiratory tract infection 15% (placebo 22.2%) back pain 2.8% (placebo 2.8%) contusion 2.8% (placebo 0.9%) NCT02489968 · Phase 3 · registry result, not featured evidence · combination 5 mg hypoglycaemia 13.2% (placebo 5.6%) nasopharyngitis 7.1% (placebo 5.6%) upper respiratory tract infection 2.2% (placebo 5.1%) NCT01792518 · Phase 3 · registry result, not featured evidence 25 mg + 5 mg nasopharyngitis 3.6% (placebo 7.3%) lipase increased 2.7% (placebo 5.5%) urinary tract infection 2.7% (placebo 6.4%) NCT01734785 · Phase 3 · registry result, not featured evidence · combination 10 mg + 5 mg urinary tract infection 7.1% (placebo 6.4%) nasopharyngitis 4.5% (placebo 7.3%) lipase increased 3.6% (placebo 5.5%) NCT01734785 · Phase 3 · registry result, not featured evidence · combination 5 mg diarrhoea 3% hyperuricaemia 3% dizziness 0% NCT01708902 · Phase 3 · registry result, not featured evidence 5 mg QD hyperglycaemia 16.9% hyperuricaemia 5.6% nasopharyngitis 5.6% NCT01708902 · Phase 3 · registry result, not featured evidence 5 mg QD hyperuricaemia 7.5% hyperglycaemia 4.8% upper respiratory tract infection 4.1% NCT01708902 · Phase 3 · registry result, not featured evidence 5 mg QD, then 2.5 mg / Metformin after week 12 hyperuricaemia 19.4% dizziness 6.5% hyperglycaemia 6.5% NCT01708902 · Phase 3 · registry result, not featured evidence · combination 2.5 mg / 1000 mg hyperuricaemia 6.2% hyperglycaemia 3.1% diarrhoea 1.5% NCT01708902 · Phase 3 · registry result, not featured evidence · combination 2.5 mg / 1000 mg BID diarrhoea 5.6% hyperuricaemia 5.6% upper respiratory tract infection 5.6% NCT01708902 · Phase 3 · registry result, not featured evidence · combination 2.5 mg / 1000 mg BID diarrhoea 9.5% hyperuricaemia 7.5% upper respiratory tract infection 7.5% NCT01708902 · Phase 3 · registry result, not featured evidence · combination 2.5 mg / 500 mg BID upper respiratory tract infection 8.2% hyperuricaemia 5.4% diarrhoea 4.8% NCT01708902 · Phase 3 · registry result, not featured evidence · combination 5 mg hyperglycaemia 10.4% nasopharyngitis 7.4% hypertension 6.7% NCT01183013 · Phase 3 · registry result, not featured evidence 5 mg + 15 mg / 5 mg + 30 mg diarrhoea 7.9% nasopharyngitis 7.1% back pain 6.3% NCT01183013 · Phase 3 · registry result, not featured evidence · combination 5 mg + 30 mg oedema 9% dizziness 6.8% oedema peripheral 6.8% NCT01183013 · Phase 3 · registry result, not featured evidence · combination 5 mg + 45 mg oedema peripheral 11.3% back pain 9% urinary tract infection 5.3% NCT01183013 · Phase 3 · registry result, not featured evidence · combination 5 mg hypoglycaemia 59.3% nasopharyngitis 18.6% hyperglycaemia 17.7% NCT01087502 · Phase 3 · registry result, not featured evidence 5 mg hyperlipidaemia 5.5% (placebo 3%) hyperglycaemia 2% (placebo 4%) NCT01214239 · Phase 3 · registry result, not featured evidence 5 mg once daily hyperglycaemia 4.9% (placebo 5%) hyperlipidaemia 4.4% (placebo 4%) diarrhoea 2.4% (placebo 1%) NCT01215097 · Phase 3 · registry result, not featured evidence 5 mg tablet anaemia 7.1% (placebo 6.7%) hyperglycaemia 6% (placebo 7.9%) hypoglycaemia 5.5% (placebo 4.5%) NCT00996658 · Phase 3 · registry result, not featured evidence nasopharyngitis 41.2% back pain 5.9% constipation 5.9% NCT01204294 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 36.6% bronchitis 11% arthralgia 6.1% NCT01204294 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 45.5% pharyngitis 7.6% constipation 4.5% NCT01204294 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 33.8% upper respiratory tract inflammation 8.1% arthralgia 5.4% NCT01204294 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 31.5% hypoglycaemia 14% contusion 7% NCT01204294 · Phase 3 · registry result, not featured evidence · combination 5 mg urinary tract infection 6.6% (placebo 3.3%) hyperglycaemia 2.8% (placebo 9.2%) NCT01194830 · Phase 3 · registry result, not featured evidence 5 mg hypoglycaemia 30.3% (placebo 31.3%) hyperglycaemia 14.3% (placebo 17.8%) nasopharyngitis 11.3% (placebo 9.8%) NCT00954447 · Phase 3 · registry result, not featured evidence linagliptin 2.5 mg bid + metformin 1000 mg bid diabetes mellitus 9.9% diarrhoea 7% nasopharyngitis 7% NCT00915772 · Phase 3 · registry result, not featured evidence · combination linagliptin 2.5 mg bid + metformin 500 mg bid hyperglycaemia 12.9% diabetes mellitus 8% glomerular filtration rate decreased 6.2% NCT00915772 · Phase 3 · registry result, not featured evidence · combination 5 mg hypoglycaemia 22.8% (placebo 16.5%) nasopharyngitis 10.5% (placebo 8.9%) diarrhoea 5.6% (placebo 2.5%) NCT01084005 · Phase 3 · registry result, not featured evidence hyperglycaemia 14.6% nasopharyngitis 9.9% dizziness 7.3% NCT00740051 · Phase 3 · registry result, not featured evidence nasopharyngitis 9.3% (placebo 8.5%) upper respiratory tract infection 3.5% (placebo 7.7%) NCT00641043 · Phase 3 · registry result, not featured evidence · combination hyperglycaemia 8.6% (placebo 22.8%) NCT00621140 · Phase 3 · registry result, not featured evidence | g nasopharyngitis 19.8% (placebo 27.4%) upper respiratory tract inflammation 5.2% (placebo 7.4%) alanine aminotransferase increased 4.2% (placebo 3.2%) NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 23 more resultsnasopharyngitis 33.3% (placebo 27.4%) protein urine present 16.7% (placebo 13.7%) glucose urine present 11.5% (placebo 17.9%) NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 nasopharyngitis 37.1% blood creatine phosphokinase increased 9.3% protein urine present 9.3% NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 nasopharyngitis 32.6% glucose urine present 18% protein urine present 14.6% NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3 nasopharyngitis 28.6% (placebo 18.3%) hypoglycaemia 27.3% (placebo 7%) constipation 10.4% (placebo 2.8%) NCT02081599 · Phase 4 · registry result, not featured evidence · combination hypoglycaemia 11.7% (placebo 7%) nasopharyngitis 7.8% (placebo 18.3%) constipation 3.9% (placebo 2.8%) NCT02081599 · Phase 4 · registry result, not featured evidence · combination 20 mg upper respiratory tract infection 11.3% (placebo 17.9%) hyperuricaemia 8.9% (placebo 10.6%) hyperlipidaemia 6.5% (placebo 5.7%) NCT02924064 · Phase 3 · registry result, not featured evidence · combination 20 mg upper respiratory tract infection 23.6% (placebo 15.7%) hyperuricaemia 8.7% (placebo 4.7%) proteinuria 7.1% (placebo 3.9%) NCT02916706 · Phase 3 · registry result, not featured evidence nasopharyngitis 30.7% pollakiuria 6.5% constipation 5.2% NCT02220907 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 15.6% (placebo 10.4%) upper respiratory tract infection 5.2% (placebo 0%) NCT02354222 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 29.2% upper respiratory tract inflammation 9.4% blood urine present 7.1% NCT01301833 · Phase 3 · registry result, not featured evidence nasopharyngitis 28% upper respiratory tract inflammation 10.7% eczema 9.3% NCT01301833 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 29.5% upper respiratory tract inflammation 10.5% blood urine present 9.5% NCT01301833 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 23.8% upper respiratory tract inflammation 13.8% bronchitis 8.8% NCT01301833 · Phase 3 · registry result, not featured evidence · combination 20 mg nasopharyngitis 6.1% (placebo 0%) blood triglycerides increased 3% (placebo 3.1%) diarrhoea 3% (placebo 0%) NCT01072331 · Phase 3 · registry result, not featured evidence 10 mg upper respiratory tract inflammation 8.8% (placebo 0%) nasopharyngitis 5.9% (placebo 0%) alanine aminotransferase increased 2.9% (placebo 0%) NCT01072331 · Phase 3 · registry result, not featured evidence 20 mg nasopharyngitis 12.1% (placebo 6.7%) glucose urine present 4% (placebo 6.7%) upper respiratory tract inflammation 4% (placebo 3.8%) NCT00998881 · Phase 3 · registry result, not featured evidence 40 mg nasopharyngitis 8% (placebo 6.8%) cystitis 5.7% (placebo 1.1%) gastroenteritis 3.4% (placebo 2.3%) NCT00971243 · Phase 2 · registry result, not featured evidence · combination 20 mg diarrhoea 5.5% (placebo 3.4%) headache 5.5% (placebo 1.1%) hypertension 3.3% (placebo 2.3%) NCT00971243 · Phase 2 · registry result, not featured evidence · combination 10 mg cystitis 4.3% (placebo 1.1%) nasopharyngitis 4.3% (placebo 6.8%) bronchitis 3.2% (placebo 1.1%) NCT00971243 · Phase 2 · registry result, not featured evidence · combination 5 mg nasopharyngitis 6.9% (placebo 6.8%) hypertension 5.7% (placebo 2.3%) bronchitis 3.4% (placebo 1.1%) NCT00971243 · Phase 2 · registry result, not featured evidence · combination 20 mg nasopharyngitis 11.4% (placebo 13.8%) glucose urine present 5.1% (placebo 7.5%) urine ketone body present 5.1% (placebo 1.3%) NCT00628212 · Phase 2 · registry result, not featured evidence 10 mg nasopharyngitis 19% (placebo 13.8%) blood creatine phosphokinase increased 4.8% (placebo 1.3%) blood urine present 4.8% (placebo 1.3%) NCT00628212 · Phase 2 · registry result, not featured evidence 40 mg nasopharyngitis 17.3% (placebo 13.8%) arthropod sting 3.7% (placebo 0%) glucose urine present 3.7% (placebo 7.5%) NCT00628212 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 4 versus Phase 3.
- cPopulation comparability has not been reviewed for both studies.
- dAssessment timepoints differ: 24 weeks versus 52 weeks.
- eTreatment context differs: monotherapy versus combination.
- fPopulation comparability has not been reviewed for 55 of these studies.
- gPopulation comparability has not been reviewed for 24 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Linagliptin
show 12 more results
show 9 more results
show 1 more result
show 4 more results
show 4 more results
show 1 more result
show 1 more result
show 7 more results
show 7 more results
+ 55 further endpoints in the CSV export.
Teneligliptin
show 5 more results
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Linagliptin's landscape · Teneligliptin's landscape